Camtek (CAMT) Q4 2025 Earnings Transcript

Camtek reported record Q4 revenue of $128.1 million, up 9% year over year, and full-year revenue of $496.9 million, up 16%, with Q4 net income rising to $40.7 million or $0.81 per diluted share. Management guided Q1 2026 revenue to about $120 million but said it expects double-digit full-year growth, stronger second-half demand, and gross margin improvement later in the year. The company also highlighted strong AI/HBM-related demand, a $25 million Hawk order, and capacity now exceeding $700 million in annual revenue potential.

Analysis

CAMT’s real inflection is not the headline revenue beat; it is that mix is shifting toward higher-spec platforms while the company is still operating below any meaningful capacity ceiling. That combination matters because it suggests management can grow into leverage without first needing a painful factory buildout, and the cash conversion improvement implies working capital is now a source of upside rather than drag. The market should also pay attention to the backlog visibility extending into 1H27: semiconductor capital equipment names rarely get credible forward demand commentary that far out unless the customer base is already locked into multi-quarter qualification and install plans.

The second-order winner set is broader than CAMT alone. OSATs, advanced packaging tool vendors, and AI memory supply-chain names benefit if HBM4 and chiplet/hybrid-bonding adoption accelerates, because each step-up in density increases inspection intensity and lowers the odds that customers can reuse older toolsets. Conversely, any competitor thesis predicated on commoditization or share loss looks weaker here: CAMT is explicitly moving from “good enough” metrology to mandatory process control for denser structures, which raises switching costs and expands wallet share even if unit growth normalizes.

The main risk is timing, not demand destruction. The stock can still wobble over the next 1-2 quarters because management itself is telegraphing a soft Q1 and heavier second-half weighting, which leaves room for multiple compression if investors over-penalize the near-term revenue trough. A more subtle risk is execution on R&D spend: if incremental operating expenses rise before the backlog converts, margins can flatten in the first half even while the long-term thesis remains intact.

Consensus is likely underestimating how much of this is a product-cycle share gain story versus a broad WFE beta story. If customers are indeed qualifying CAMT into additional steps, then the upside is not just more systems shipped, but a larger revenue per customer over time — a materially better earnings lever than simple market growth. That makes the correct framing less “how much does WFE grow?” and more “how quickly does CAMT become a must-have across the next HBM/advanced packaging transition,” which could support multiple expansion if evidence continues into mid-2026.

Key Decisions for Investors

• Long CAMT into any post-earnings weakness over the next 2-6 weeks; thesis is second-half reacceleration and share gain, with a favorable setup if the market over-focuses on soft Q1. Risk: multiple compression if orders slip, so keep size modest and add only on confirmation of Q2 visibility.
• Buy CAMT vs. short a broader semiconductor equipment basket over 3-6 months; CAMT has more idiosyncratic AI/advanced-packaging torque and less exposure to a generic WFE reset. This works best if the market starts paying up for product-cycle winners instead of broad cyclicals.
• Use CAMT call spreads for a 3-9 month horizon rather than outright stock if you want convexity on the H2 ramp; the setup is attractive because downside is cushioned by cash and operating performance, while upside is tied to backlog conversion. Prefer strikes that monetize a re-rating on 2H guidance clarity.
• Monitor OSAT and advanced-packaging beneficiaries for a relative-long basket trade, but favor CAMT as the highest-quality enabler. If packaging capex remains broad, CAMT should outperform less differentiated process-control peers because it is already embedded at multiple customer steps.
• If CAMT rallies sharply on the print, consider trimming only if the market fully prices in 2026 growth; the risk-reward shifts once the stock discounts the second-half ramp before evidence arrives. Otherwise, hold for 1H26 validation and 2027 order commentary.